Assembly Biosciences (NASDAQ:ASMB) Price Target Cut to $45.00 by Analysts at Mizuho

Assembly Biosciences (NASDAQ:ASMB) had its target price lowered by investment analysts at Mizuho from $53.00 to $45.00 in a report issued on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s price objective suggests a potential upside of 34.69% from the company’s previous close.

Several other research firms have also recently commented on ASMB. UBS Group assumed coverage on Assembly Biosciences in a research note on Tuesday. They issued a “buy” rating and a $52.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Tuesday, August 18th. Guggenheim reiterated a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a research report on Thursday, May 28th. Zacks Research raised shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Assembly Biosciences has an average rating of “Moderate Buy” and a consensus target price of $45.60.

Assembly Biosciences Stock Down 0.7%

NASDAQ:ASMB traded down $0.22 during mid-day trading on Tuesday, reaching $33.41. 60,448 shares of the company were exchanged, compared to its average volume of 162,081. The stock has a market cap of $680.23 million, a PE ratio of 33.01 and a beta of 1.10. Assembly Biosciences has a 12 month low of $20.23 and a 12 month high of $39.71. The company has a fifty day moving average of $28.38 and a 200 day moving average of $27.94.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The company had revenue of $13.37 million for the quarter, compared to analyst estimates of $8.60 million. On average, equities research analysts anticipate that Assembly Biosciences will post 2.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Assembly Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in ASMB. RA Capital Management L.P. bought a new position in Assembly Biosciences during the 3rd quarter worth about $26,122,000. Janus Henderson Group PLC boosted its position in shares of Assembly Biosciences by 1.4% during the first quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock worth $23,479,000 after buying an additional 11,384 shares during the period. Paradigm Biocapital Advisors LP bought a new position in shares of Assembly Biosciences during the fourth quarter worth about $22,625,000. Vanguard Group Inc. raised its position in Assembly Biosciences by 97.8% in the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after buying an additional 248,287 shares during the last quarter. Finally, Seven Fleet Capital Management LP raised its position in Assembly Biosciences by 671.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock valued at $11,903,000 after buying an additional 377,000 shares during the last quarter. 19.92% of the stock is currently owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.